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ABSTRACT: Exposure toCOcauses early afterdepolarization arrhythmias. Previous studies in rats have indicated that
arrhythmias arose as a result of augmentation of the late Na+ current. The purpose of the present study was to
examine thebasis forCO-inducedarrhythmias inguineapigmyocytes inwhichactionpotentials (APs)more closely
resemble those of human myocytes. Whole-cell current- and voltage-clamp recordings were made from isolated
guinea pigmyocytes aswell as fromhuman embryonic kidney 293 (HEK293) cells that expresswild-type or aC723S
mutant form of ether-a-go-go–related gene (ERG; Kv11.1). We also monitored the formation of peroxynitrite
(ONOO2) in HEK293 cells fluorimetrically. CO—applied as the CO-releasingmolecule, CORM-2—prolonged the
APs and induced early afterdepolarizations in guinea pig myocytes. In HEK293 cells, CO inhibited wild-type, but
not C723S mutant, Kv11.1 K+ currents. Inhibition was prevented by an antioxidant, mitochondrial inhibitors, or
inhibition of NO formation. CO also raised ONOO2 levels, an effect that was reversed by the ONOO2 scavenger,
FeTPPS [5,10,15,20-tetrakis-(4-sulfonatophenyl)-porphyrinato-iron(III)], which also prevented the CO inhibition of
Kv11.1 currents and abolished the effects of CO on Kv11.1 tail currents and APs in guinea pig myocytes. Our data
suggest that CO induces arrhythmias in guinea pig cardiac myocytes via the ONOO2-mediated inhibition of
Kv11.1 K+ channels.—Al-Owais, M. M., Hettiarachchi, N. T., Kirton, H. M., Hardy, M. E., Boyle, J. P., Scragg,
J. L., Steele,D. S., Peers, C.Akey role for peroxynitrite-mediated inhibition of cardiac ERG (Kv11.1) K+ channels in
carbonmonoxide–induced proarrhythmic early afterdepolarizations. FASEB J. 31, 000–000 (2017). www.fasebj.org
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Endogenous CO production occurs via degradation of
heme by heme oxygenases (HO)-1 and -2 to provide
protection from cellular stresses (1, 2). Endogenous
cardiac CO provides cardioprotection, which limits the
cellular damage of ischemia/reperfusion (I/R) injury
(3). HO-1 knockout increases cardiac damage after I/R
injury (4), whereas HO-1 overexpression decreases (5)
cardiac damage after I/R injury. Thus, CO has numerous
beneficial actions in the heart, vasculature, and other
systems (6, 7), many of which are mediated by its ac-
tions on distinct ion channels (8, 9); however, despite
the beneficial effects of endogenous CO, exposure to
exogenous CO is hazardous. CO poisoning accounts
for more than 50% of fatal poisonings (10–12) and a
large-scale U.S. survey clearly established an associa-
tion between ambient CO and increased risk of hos-
pitalization as a result of cardiovascular complaints,
including arrhythmias (13). This supports previous
studies that have implicated environmental CO ex-
posure in myocardial dysfunction (14, 15). Chronic,
lower-level exposure to CO produces cardiac injury
and fibrosis (16, 17), and acute environmental expo-
sure can lead to arrhythmias and risk of associated
sudden death (15, 18).
ABBREVIATIONS: AP, action potential; APD, action potential duration;
APF, 2-[6-(49-amino)phenoxy-3H-xanthen-3-on-9-yl] benzoic acid; CORM-2,
CO-releasing molecule; EAD, early afterdepolarization; ERG, ether-a-
go-go–related gene; FeTPPS, 5,10,15,20-tetrakis-(4-sulfonatophenyl)-por-
phyrinato-iron(III); HEK293, human embryonic kidney 293; HO, heme
oxygenase; iCORM, inactive CO-releasing molecule; I/R, ischemia/
reperfusion; L-NAME, L-NG-nitroarginine methyl ester; LQT, long QT
syndrome; ROS, reactive oxygen species
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Ion channels are a major group of proteins that is mod-
ulated by CO, which occurs via numerous signaling path-
ways (8). In rat cardiac myocytes, we have demonstrated
that CO promotes early afterdepolarization (EAD)–like ar-
rhythmias thatare reminiscentof longQTsyndrome(LQT)-
3 arrhythmias by increasing the amplitude of the late Na+
current, INaL (19), an effect that is attributable to the acti-
vation of NO formation by nNOS (20) and subsequent
S-nitrosylation of the channel. Other studies have
shown that CO inhibits the cardiac L-type Ca2+ current
(21) and inward rectifier K+ current (22), each by distinct
mechanisms. These studies highlight the fact that the
Figure 1. CO induces EAD-like arrhythmias in guinea pig myocytes. A) Example APs evoked in a guinea pig myocytes before
(control) and after 3 min of exposure to the CO donor, CORM-2 (10 mM; left). Means 6SEM percentage changes in APD caused by
10 mM CORM-2 after 3 min (n = 14; right). B) Time course plot of the increase in APD50 caused by 10 mM CORM-2 (open symbols,
n = 14) and 10 mM iCORM (solid symbols; n = 5). Each point is the mean6SEM percentage change in APD50 duration. C) Example
APs evoked in a guinea pig myocyte before (control) and after 5 min of exposure to the iCORM (10 mM; left). Means 6SEM
percentage changes in APD caused by 10 mM iCORM after 5 min (n = 5; right). D) Examples of evoked APs during more
prolonged exposure to CORM-2. Note the emergence of EAD-like AP. E) Example APs evoked in a myocyte before (control) and
after 4 min of exposure to E-4031 (1 mM; top). Means 6 SEM percentage changes in APD caused by 1 mM E-4031 after 5 min (n =
6; bottom). F) Example APs evoked in a myocyte before (control) and after 3 min of exposure to CORM-2 (10 mM), then after
5 min exposure to NS1643 (1 mM) in the continued presence of CORM-2 (top). Means 6SEM percentage changes in APD caused
by 10 mM CORM-2 alone (solid bars) and in the presence of 1 mMNS1643 (n = 6; bottom). **P, 0.01; ***P, 0.001, determined
by paired Student’s t tests of control (predrug) values and those observed in the presence of drugs applied to the same cells.
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Figure 2. CO inhibits recombinant hERG. A) Illustration of the voltage-clamp protocol used to generate the fully activated current-
voltage relationships in HEK293 cells (top). Example families of currents evoked by this protocol in HEK293 cells that stably express
hERG before (control) and after (CORM-2) exposure of cells to 3 mMCORM-2 (bottom). B) Means6 SEM current voltage-relationships
obtained from cells before (solid circles, n = 9) and during exposure to CORM-2 (3 mM; open circles, n = 9) or iCORM (3 mM; open
triangles, n = 8). C) Concentration-response relationship obtained by determining the percent inhibition of the hERG tail current
caused by CORM-2 as determined by using a 2-step pulse protocol of 2 s of depolarization to +40 mV followed by a 2-s step to240 mV
from a holding potential of280 mV and applied every 10 s. Each point plotted is the mean6 SEM taken from between 3 and 6 cells. D)
Time-series plot in which normalized peak tail current amplitudes, evoked by successive step depolarizations as indicated in panel C, are
plotted against time (left). For the periods indicated by the horizontal bars, cell was exposed to 3 mM CORM-2 or 3 mM NS1643, as
indicated. Superimposed example traces from the same experiment that illustrate the effects of CORM-2 and NS1643, as indicated
(center). Mean6 SEM (n = 5) percentage inhibition of the peak tail current caused by 3 mM CORM-2 alone (white bar) and reversal of
this inhibition by 3 mM NS1643 (gray bar; right). **P , 0.01, signiﬁcant reversal of CORM-2–inhibited current amplitudes by NS1643
(comparing white and gray bars). E) Time-series plot evoked as in panel D, but in this case the cell was exposed to 3 mM E-4031.
Superimposed example traces from the same experiment that illustrate the effect of E-4031, as indicated (inset). F) Same as panel E,
except that the cell was exposed to 3 mM iCORM.
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proarrhythmic effects of COare complex and involve the
regulation of multiple ion channels; however, their trans-
lational impact is limited because all studies to date have
been conducted in rat cardiac myocytes, and there are
major electrophysiologic differences between rat cardiac
myocytes and those from larger mammals, including hu-
mans. In particular, the plateau phase of the ventricular
action potential (AP) is brief or absent in rat myocytes (23,
24) comparedwith guinea pigmyocytes. This presumably
arises from differences in expression—and relative ex-
pression levels—of ion channels that contribute to the AP.
One key ion channel, ether-a-go-go–related gene (ERG)
(Kv11.1), which is primarily responsible for myocyte re-
polarization (giving rise to the K+ current IKr), seems to be
expressed at low levels in rat tissue (23, 24) but is prom-
inent in other species, such as guinea pig and human. The
importance of Kv11.1 is reflected in the fact that numerous
ERG mutations give rise to LQT-2, one of the most com-
mon forms of long QT syndrome, which increases pa-
tients’ vulnerability to arrhythmias and sudden death
(25–29). Furthermore, the U.S. Food and Drug Adminis-
tration requires that all new drugs be tested for LQT-
associated cardiac risk (30), as so many diverse drugs
modulate this channel [reviewed previously (30–32)],
which causes acquired LQT syndrome, a major safety
challenge for the pharmaceutical industry. Here, we ex-
plore the ability of CO to modulate recombinant human
(h)ERG channels and assess the potential arrhythmic im-
pact of such modulation on ventricular myocytes from
guinea pigs, which abundantly express Kv11.1 and dis-
play a prominent AP plateau phase that is reminiscent of
human tissue.
MATERIALS AND METHODS
Isolation of guinea pig myocytes
DunkinHartley guinea pigs (300–350 g; Charles River UK, Kent,
UnitedKingdom)were euthanized inaccordancewithUKHome
Office Guidance on the Operation of Animals (Scientific Proce-
dures)Act 1986 and institutional guidelines. Isolated heartswere
perfused via the aorta with warm (37°C), oxygenated tyrode so-
lution that contained (in mM) 135 NaCl, 6 KCl, 0.33 NaH2PO4,
5 Na pyruvate, 1 MgCl2, 10 HEPES, and 10 glucose, adjusted to
pH 7.4 with NaOH, for 5 min in the absence of Ca2+. To disag-
gregate cells, each heart was perfused with Ca2+-free tyrode so-
lution that contained collagenase type II (100 U/ml; Worthington,
Lorne, VIC, Australia), protease (0.66mg/ml; Sigma-Aldrich, St.
Louis, MO, USA), and bovine serum albumin (1.66 mg/ml;
Sigma-Aldrich) for 10min, thenwashedwith1mMCa2+-containing
tyrode solution for 5 min. Ventricles were minced and gently
shaken every 5 min in the latter solution. Cells were maintained
in 2 mM Ca2+-containing tyrode solution.
Expression of hERG in human embryonic kidney
293 cells
Human embryonic kidney 293 (HEK293) cell lines that stably
express hERG1a (Kv11.1) were generated by using a pCEP4
plasmid that contained hERG cDNA and transfected by using a
Figure 3. CO inhibition of hERG involves
mitochondrial ROS. A) Superimposed example
currents from the same cell that illustrate the
lack of effect CORM-2 (3 mM) after pretreat-
ment of the cell with 100 nM ebselen for 30 min
(left). Means 6 SEM (n = 5) percentage in-
hibition of the peak tail current caused by 3 mM
CORM-2 after pretreatment with 100 nM
ebselen (right). B, C) Same as panel A, except
that cells were pretreated with either antimycin
A (B; n = 5) or myxothiazol (C; n = 6; both at
1 mM for 1 h at 37°C). N.s., not signiﬁcant
compared with paired t tests of amplitudes
before and during CORM-2 application.
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lipofectamine method (Thermo Fisher Scientific, Waltham, MA,
USA).Ahygromycin resistancegenewasused for the selectionof
stable lines. Single colonies were picked and examined for hERG
currents byusingwhole-cell patch-clamp recordings (see below).
Positive clones were cultured in minimum essential medium
(Thermo Fisher Scientific) that was supplemented with fetal
bovine serum(10%), nonessential aminoacids (1%), an antibiotic
antimycotic mix (1%), glutamax (1%; Thermo Fisher Scientific),
and hygromycin (100 mg/ml; Calbiochem, San Diego, CA,
USA). C723S mutation was introduced using the QuikChange
***
***
***
Figure 4. CO inhibition of hERG involves the formation of peroxynitrite. A) Time-series plot in which normalized peak tail
current amplitudes, evoked by step depolarizations from 280 mV to +40 mV followed by a repolarization to 240 mV, are plotted
against time. For the period indicated by the horizontal bar, the cell was exposed to 3 mM CORM-2, as indicated. Before this
recording, the cell was pretreated with 1 mM L-NAME for 1 h at 37°C. Superimposed example currents from the same cell that
illustrate the lack of effect CORM-2 (3 mM) after pretreatment of the cell with L-NAME (inset). Mean 6 SEM (n = 7) percentage
inhibition of the peak tail current caused by 3 mM CORM-2 after pretreatment with 1 mM L-NAME (right). B) Example
recordings of APF ﬂuorescence monitored in HEK293 cells that stably express hERG. At the point indicated by the arrow, cells
were exposed to CORM-2, iCORM, and CORM-2 after pretreatment with 25 mM FeTPPS for 1 h at 37°C or CORM-2 after
pretreatment with 1 mM L-NAME for 1 h at 37°C, as indicated. C) Bar graph plots means 6 SEM (determined from 5 or 6
recordings in each case) APF ﬂuorescence determined at room temperature after exposure of cells to CORM-2, iCORM, or
CORM-2 in FeTPPS- or L-NAME–pretreated cells. Control (open bar) represents time-matched recordings during which no
drugs were added. ***P , 0.001, unpaired Student’s t test comparisons vs. effects of CORM-2. D) Time-series plot as in panel A,
except that the cell was pretreated with 25 mM FeTPPS 1 h. Superimposed example currents from the same cell that illustrate the
lack of effect CORM-2 (3 mM) after pretreatment of the cell with FeTPPS (inset). Mean 6 SEM (n = 6) percentage inhibition of
the peak tail current caused by 3 mM CORM-2 after pretreatment with 25 mM FeTPPS (right). n.s., not signiﬁcant compared with
paired Student’s t test of amplitudes before and during CORM-2 application.
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site-directed mutagenesis kit (Stratagene, Cambridge, United
Kingdom) according to manufacturer instructions. All con-
structs were verified by DNA sequence analysis.
Electrophysiology—recombinant hERG
Coverslip fragments with attached cells were transferred to a
perfused (3–5 ml/min) recording chamber that was mounted on
anOlympusCK40 invertedmicroscope (Olympus, Tokyo, Japan).
The chamber (80–100 ml volume) was perfused at room temper-
ature (21–23°C)with a solution thatwas composedof (inmM)140
NaCl, 4 KCl, 1.8 CaCl2, 1MgCl2, 10HEPES, and 10 D-glucose (pH
adjusted to 7.4 with NaOH). Whole-cell patch-clamp recordings
weremade by using patch pipettes of 4- to 7-MV resistance when
filledwith the intracellular solution thatwas composedof (inmM)
110 KCl, 10 NaCl, 10 EGTA, 1 MgCl2, 10 HEPES, and 5 MgATP
(pH 7.2, KOH). Series resistance was compensated for by 60–90%
and hERG currents were fully activated by using a 1-s prepulse to
+40mV followed by depolarizing steps that ranged from2100 to
+40 mV applied in 10-mV increments for 3 s (holding potential of
280mV;Fig. 2A).Currentsweremeasuredat theendof the3-s test
pulsewithout any corrections for residual voltage errors. For time
series plots (e.g., Fig. 2D), hERG tail currents were repeatedly ac-
tivatedbyusinga2-s stepdepolarization to+40mVapplied froma
holdingpotential of280mV, followedbya2-spulse to240mVto
record tail currents, before repolarization to280mV.All protocols
were applied at 0.1 Hz.
Electrophysiology—cardiac myocytes
Myocytes were perfused after settling in the perfusion chamber.
Perfusionandpipette compositionwasexactlyasused inHEK293
cell recordings. Myocytes were voltage clamped at240 mV and
step depolarized to +20 mV for 750 ms before repolarization to
240 mV. IKr—that is, the outward K
+ current passing through
ERG channels—was evident as a tail current observed after re-
polarization (33–35).APswereevoked incurrent-clampmode (I=
0) by applying supramaximal depolarizing current injections
(5-ms duration, 0.1 Hz). AP duration (APD) at 20, 50, and 90% of
maximal amplitude was measured. Percent change was calcu-
lated as follows: (APD in the presence of drug/control APD) 3
100. Statistical analysis was performed by using paired Student’s
t tests, where P, 0.05 was considered significant.
Peroxynitrite detection
Attached cells on coverslipswere incubatedwith 2-[6-(49-amino)
phenoxy-3H-xanthen-3-on-9-yl] benzoic acid (APF; 10 mM) that
was dissolved in HEPES-buffered saline for 1 h at 37°C in the
dark. Coverslip fragments were placed on a glass slide that
contained 200 ml HEPES-buffered saline with 10 mM APF.
Changes in fluorescence intensity weremeasured over 10min
by using a Zeiss laser scanning confocalmicroscope (LSM510;
Zeiss, Oberkochen, Germany). APF was excited at 488 nm,
emissionwasmonitored at 510 nm, and imageswere obtained
by using Zeiss AIM software. Identical settings were used for
each test condition. For APF experiments that involved L-NG-
nitroarginine methyl ester (L-NAME), cells were incubated
with both 10 mM APF and 1 mM L-NAME for 1 h at 37°C
before recording. Experiments that involved FeTPPS
[5,10,15,20-tetrakis-(4-sulfonatophenyl)-porphyrinato-iron
(III)] used cells that were incubated with both 10 mM APF
and 25 mM FeTPPS for 1 h at 37°C.
RESULTS
Figure 1A shows representative APs that were evoked
in a guinea pig myocyte before and during bath ap-
plication of the CO donor, CO-releasing molecule 2
(CORM-2; 10 mM). In the presence of CORM-2, APD
gradually increased as quantified at 3 min in Fig. 1A.
The time course of increase is shown in Fig. 1B for
APD50. Also plotted in Fig. 1B (example in Fig. 1C) is
the lack of effect of the inactive compound, inactive
CORM (iCORM). In all 11 myocytes in which the ef-
fects of CORM-2 were followed for .5 min, EAD ar-
rhythmias were observed (Fig. 1D). Qualitatively
similar increases in APD were observed during expo-
sure to the ERG inhibitor, E-4031 (1 mM; Fig. 1E).
Furthermore, the effect of CORM-2 to prolong APD
was fully reversed by the ERG activator, NS1643 (Fig.
1F). Collectively, these findings suggest that the
proarrhythmic effects of CO in guinea pig myocytes
may arise as a result of the inhibition of ERG channels.
To explore the modulation of ERG currents by CO in
isolation without contamination from other native currents
in myocytes, we stably expressed the human isoform
(hERG) in HEK293 cells. Depolarization evoked robust
outward currents, with tail currents evoked by re-
polarization to different potentials, as illustrated in Fig. 2A.
At more positive repolarization values, tail currents were
characteristically larger than those that were observed
Figure 5. hERGC723S mutant is insensitive to CO.
Time-series plot in which normalized peak tail
current amplitudes, evoked by successive step
depolarizations from 280 mV to +40 mV followed
by a repolarization to 240 mV, are plotted against
time. For the period indicated by the horizontal
bar, the cell was exposed to 3 mM CORM-2, as
indicated. This recording was obtained from a
HEK293 cell that was stably transfected with a
C723S mutant form of hERG. Superimposed
example currents from the same cell that
illustrate the lack of effect CORM-2 (3 mM) on
the C723S mutant form of the channel (inset).
Mean 6 SEM (n = 5) percentage inhibition of the
peak tail current caused by 3 mMCORM-2 in cells
that express the C723S mutant form of hERG
(right). N.s., not signiﬁcant compared with paired
t test of amplitudes before and during CORM-2
application.
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during depolarizing pulses as a result of the relief of rapid
inactivation that occurs before deactivation (Fig. 2A). Cur-
rentsatallAPswere reduced inamplitudeby3mMCORM-2
(Fig. 2A, B), and after determining a concentration-response
relationship (Fig. 2C), this concentration was used for addi-
tional experiments.
Note the lack of effect for 3 mM iCORM (Fig. 2B). Unless
otherwise stated, we then employed a protocol of step de-
polarizations that were applied repeatedly from280mV to
+40 mV for 2 s, followed by repolarization to240 mV. Re-
sultant tail currents were measured at their peak. This
protocol highlighted that inhibition by CORM-2 was es-
sentially irreversible over periods that ranged from 3 to
5 min (Fig. 2D); however, current amplitudes were recov-
ered by the ERG activator, NS1643 (Fig. 2D, E). Currents
were also strongly inhibitedbyE-4031 (Fig. 2E; 3mMcaused
756 5.5% inhibition; n= 4;P, 0.001) farmore rapidly than
by CORM-2 (compare Fig. 2D, E). Currents that were
evoked by repeated step depolarizations were essentially
unaffected by iCORM (Fig. 2F, representative of 6 cells).
CO regulates ion channels via numerous mechanisms
(15). The ability of CORM-2 to inhibit recombinant hERG
Figure 6. CO inhibits native
ERG in guinea pig myocytes.
A) Example currents in a
guinea pig ventricular myocyte
evoked by step depolarization
from 240 mV to +20 mV, then
repolarization to 240 mV. The
current attributable to ERG
channels is the transient out-
ward current observed on re-
polarization. The horizontal
line in all traces of this ﬁgure
(A–C, E) indicate 0 current
level. Two superimposed re-
cordings are shown: before
and during exposure of the
myocyte to 1 mM E-4031. B,
C). Same as panel A, except
that cells were exposed either to
CORM-2 (10 mM; B) or iCORM
(10 mM; C). D) Bar graph
plotting mean 6 SEM (n = 5–11
in each case) percentage in-
hibition of the peak tail current
amplitude caused by applica-
tion of E-4031, CORM-2, and
iCORM (as exempliﬁed in pan-
els A–C). ***P , 0.001, paired
Student’s t tests of control vs.
drug treatments. E) Same as
panel B, except the cell was
pretreated for 1 h at 37°C with
25 mM FeTPPS (left). Mean 6
SEM (n = 9) percentage inhibi-
tion of the peak tail current
caused by 10 mM CORM-2 in
cells that were pretreated for
1 h at 37°C with 25 mM FeTPPS
(right). F) Example APs evoked
in a guinea pig myocyte pre-
viously pretreated for 1 h at
37°C with 25 mM FeTPPS be-
fore (control) and during ex-
posure to 10 mM CORM-2 for
the times indicated (top). Bar
graphs plotting normalized
APD50 and APD90 values be-
fore (open bars) and during
(solid bars) exposure to 10 mM
CORM-2 (bottom). Cells were
either pretreated with 25 mM
FeTPPS for 1 h (as indicated) or did not receive pretreatment. **P , 0.01 compared with paired t tests of APDs before and during
CORM-2 application. G) Example APs recorded in a guinea pig myocyte before drug exposure (control), after 9 min of exposure to
10 mM CORM-2, and after 5 min of exposure to 20 mM ranolazine, which was applied immediately after CORM-2 (top). Bar graph
plotting mean6 SEM (n = 5) number of EAD-like APs recorded in myocytes over a period of 10 min during CORM-2 exposure, and
during ranolazine exposure, as indicated (bottom). N.s., not signiﬁcant. *P , 0.05, unpaired Student’s t test.
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was blocked by the antioxidant ebselen (100 nM; Fig. 3A),
which indicates the likely involvement of reactive oxygen
species (ROS). Mitochondria represent a major source of
ROS that can be increased by CO (18). To investigate their
involvement, we examined the effects of 2 mitochondrial
inhibitors. Pretreatment of cells with either antimycin A
(Fig. 3B) or myxothiazol (Fig. 3C)—both applied at 1 mM
for 1 h at 37°C—almost fully prevented the inhibition of
hERG by CORM-2, which suggests that CO-mediated in-
hibition of hERG involves mitochondria-derived ROS.
We also investigated the role of NO in CO inhibition of
hERG, as NO mediates increases in INaL by CO in rat
cardiac myocytes (16). Pretreating cells with 1 mM
L-NAME (1 h, 37°C) to prevent NO formation abolished
the inhibitory effects ofCORM-2 (Fig. 4A),which indicates
that CO inhibition of hERG requires NO formation. The
dependence of CO inhibition of hERG on both ROS and
NO raised the possibility that CO stimulates formation of
peroxynitrite (ONOO2); therefore, we investigated
whether CO could generate detectable levels of ONOO2
by using the ONOO2 sensitive fluoroprobe, APF. As
shown in Fig. 4B, CORM-2, but not iCORM, evoked an
increase in APF fluorescence, which was indicative of
ONOO2 formation that was abolished by pretreat-
ment of cells with L-NAME as well as by the ONOO2
scavenger, FeTPPS [5,10,15,20-tetrakis-(4-sulfonatophenyl)-
porphyrinato-iron(III); 25 mM], which converts ONOO2 to ni-
trate (36).MeanAPFdata areplotted inFig. 4C. Pretreatment of
cells with FeTPPS (1 h at 37°C, 25 mM) also prevented the
inhibitionofhERGbyCORM-2 (Fig. 4D).Our findings strongly
suggest that CO inhibited hERG viaONOO2-mediated oxida-
tion. Previous studies have shown that cysteine 723 is a C-
terminal residue that confers sensitivity to oxidants (37). We
generated a C723S mutant to explore the involvement of this
residue in CO sensitivity of hERG. As seen in Fig. 4D, thismu-
tant form of hERGwas insensitive to CORM-2 (Fig. 5).
Collectively, our findings suggest that CO inhibition of
ERG (Kv11.1) can account for the proarrhythmic effects in
guinea pig myocytes. To further investigate this, we ex-
amined the ability of CORM-2 to inhibit IKr (corresponding
to Kv11.1) in guinea pig myocytes. Following established
protocols (35), currents were obtained by using depolariz-
ingsteps to+40mVfor750ms, followedbyarepolarization
to 240 mV from a holding potential of 280 mV. These
outward currents weremarkedly reduced by 1 mME-4031
(Fig. 6A, D). Similarly, CORM-2 (10 mM) reduced these
outward currents (Fig. 6B, D); however, iCORM (10 mM)
was without effect (Fig. 6C, D). Of importance, pre-
exposure (30 min, 37°C) of guinea pig myocytes to
FeTPPs (25mM) abolished the subsequent effects of 10mM
CORM-2 on transient outward currents (Fig. 6E). Thus,
native ERG currents in myocytes seemed to be inhibited
by CO via the same mechanism as that observed for re-
combinant hERG—that is, via the formation of ONOO2.
We also observed that the effects of CORM-2 on APD
were abolished by FeTPPs (Fig. 6F). Finally, ranolazine
(20 mM), an inhibitor of INaL that reverses the arrhythmic
effects of CO in rat myocytes (19), did not prevent the
proarrhythmic effects of CO in guinea pig myocytes. In
these experiments, APs were evoked and CORM-2 was
applied for a period of 10 min. During this period, the
number of clear EAD-like APs (as exemplified in Fig. 6G)
was averaged (see bar graph). Then, the perfusate was
switched to one that contained ranolazine (20 mM). Over
the following 10 min, the incidence of EAD-like APs sig-
nificantly increased (Fig. 6G), which suggests that modu-
lation of ERG (Kv11.1) is the dominant mechanism that
underlies the proarrhythmic effects of CO in guinea pig
myocytes.
DISCUSSION
The present study demonstrates that inhibition of ERGK+
channels is the dominant proarrhythmic effect of CO in
guinea pigmyocytes. Results are consistent with previous
studies that have reported that CO prolongs ventricular
APD (19, 22), but the underlying mechanisms are strik-
ingly different. Previously, reports have indicated that CO
increased INaL (19) or inhibited inward rectifierK
+ currents
(22) to prolongAPD, but these studies used rat ventricular
myocytes in which the activity of ERG channels is negli-
gible (24, 38). Rat and mouse myocytes are valuable, the
latter particularly for transgenic studies, but their brief
APD—and channel expression profile—compared with
human cardiac APD, limits their translational value. By
contrast, guinea pig myocyte APs display a significant
plateau phase that is reminiscent of human ventricular
tissue (39) and express functionally important ERG K+
channels that are comparable to hERG (35).
Clearly, multiple signaling pathways mediate the CO
regulation of ion channels in cardiac myocytes: L-type Ca2+
channels are inhibited by CO via mitochondrial ROS for-
mation (21), whereas augmentation of INaL by CO required
NO formation (19). In guinea pig myocytes, CO increases
bothNO(Fig. 4) andmitochondrialROSproduction (Fig. 3),
which form ONOO2 to inhibit ERG channels via oxidation
of C723 (Fig. 5). Liang et al. (22) indicated that CO inhibits
inward rectifier K+ channels by disrupting their interaction
with phosphatidylinositol (4, 5)-bisphosphate, although the
underlying signaling pathway was not explored. Thus, it
seems that CO can regulate multiple cardiac myocyte ion
channels via different signaling pathways, and that each of
these could individually contribute to the remodeling of the
APshapeandduration.Thepresent studydoesnotdiscount
any of these alternate pathways or ion channel targets as
contributory factors to the overall effect observed in guinea
pig myocytes, but suggests strongly that CO inhibition of
Kv11.1 is of major importance.
In rats, INaL augmentation by CO is central to its
proarrhythmic effects, the reversal of which was achieved
by ranolazine, an inhibitor of INaL. The present study
suggests that augmentation of INaL does not contribute
significantly to APD prolongation and EAD-like arrhyth-
mias in guinea pig myocytes, as these were exacerbated
and not reversed by ranolazine (Fig. 5). Exacerbation, al-
though not studied further, is consistent with earlier work
(40) and may be attributable to the inhibition of ERG
channels by ranolazine (41, 42). Furthermore, FeTPPS
prevented the arrhythmic activity and inhibition of ERG
channels by CO in guinea pig myocytes (Fig. 5), but aug-
mentation of INaL byCO in rats occurred independently of
8 Vol. 31 November 2017 AL-OWAIS ET AL.The FASEB Journal x www.fasebj.org
 Vol.,  No. , pp:, September, 2017The FASEB Journal. 129.11.22.210 to IP www.fasebj.orgDownloaded from 
ROS formation (19). These findings do not preclude the
idea that CO can induce ONOO2 formation in rat cardiac
myocytes. Instead, they suggest that ERG channels seem
to be particularly sensitive to ONOO2, an effect that is
undetectable in rats because of their extremely low ex-
pression. It is conceivable that colocalization of mito-
chondria (the source of ROS), NOS, and ERG channels
favors localized ONOO2 formation, which is sufficiently
close to ERG channels to cause their selective inhibition.
Alternatively, ERG channels might discriminate between
different ROS. We consider this highly unlikely, as hERG
can be modulated by ROS generated by various experi-
mental means (37, 43).
Currently, it is unclear how to reconcile the proar-
rhythmic effects of CO described here and elsewhere (19)
with the reported cardioprotective effects of HO-1 in-
duction,manyofwhichare attributable toCO(9).Cardiac
I/R injury is worsened in HO-1+/2 mice (44), whereas
HO-1 overexpression provides protection (5), and this
protective effect was also observed after the administra-
tion of the water-soluble CO donor, CORM-3 (3, 45). In-
deed, CORM-3 has a positive inotropic effect on the
isolated rat heart (46). This effect, which was not mim-
icked by amore slowly actingCOdonor,was attributable
to the activation of cyclic GMP and could also be abol-
ished by the inhibition of Na+/H+ exchange. Neither
mechanism is involved in the modulation of ERG—or
other relevant channels—in myocytes. Details of APs
were not investigated. These cardioprotective effects of
CO suggest that it may have therapeutic potential; how-
ever, it is clear from the present study that the current
understanding of how CO affects cardiac excitability and
function is far from complete, particularly as rat tissue has
been the chief source of information to date. Our findings
suggest that interventions that target/restore ERG activ-
itymayprovide a novel and effective approach to treating
CO-induced arrhythmias in humans.
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